Title : Characterization of low-grade arthralgia, myalgia, and musculoskeletal pain with ibrutinib therapy: pooled analysis of clinical trials in patients with chronic lymphocytic leukemia and mantle cell lymphoma.

Pub. Date : 2022 Feb 28

PMID : 35227147






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Joint and muscle pain, including arthralgia, myalgia, and musculoskeletal pain, are among the common adverse events (AEs) reported for ibrutinib, a once-daily Bruton"s tyrosine kinase inhibitor approved for the treatment of various B-cell malignancies, including chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). ibrutinib Bruton tyrosine kinase Homo sapiens